1. Home
  2. HOVR vs RLYB Comparison

HOVR vs RLYB Comparison

Compare HOVR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Horizon Aircraft Ltd.

HOVR

New Horizon Aircraft Ltd.

HOLD

Current Price

$1.74

Market Cap

80.6M

Sector

Finance

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$15.82

Market Cap

92.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HOVR
RLYB
Founded
2013
2018
Country
Canada
United States
Employees
30
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.6M
92.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HOVR
RLYB
Price
$1.74
$15.82
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$10.33
N/A
AVG Volume (30 Days)
1.1M
39.3K
Earning Date
04-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$1.16
$0.39
52 Week High
$4.18
$17.57

Technical Indicators

Market Signals
Indicator
HOVR
RLYB
Relative Strength Index (RSI) 36.24 55.98
Support Level $1.72 $15.59
Resistance Level $1.91 $16.50
Average True Range (ATR) 0.13 0.37
MACD -0.02 -0.13
Stochastic Oscillator 11.97 18.68

Price Performance

Historical Comparison
HOVR
RLYB

About HOVR New Horizon Aircraft Ltd.

New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: